Title: A study on potential stem cell markers’ expression in ovarian and uterine cancer
Abstract: Background CD44 and CD24 are two markers that are currently supposed to be expressed in certain combinations (CD44+/CD24-/low) in cells with stem-cell properties in different types of cancer. Our research was focused on identification of these two markers in ovarian and uterine cancer. Materials and methods The archived materials of formalin-fixed, paraffin-embedded tissues were used for research. The cases were divided according to the morphologic differentiation: low (I group), moderate (II group) and high differentiated (III group) variants (10 cases of each type). The H&E and CD24/CD44 immunohistochemically stained parallel slices were evaluated. Results The results showed non-specific expression features in uterine cancer cases [CD44 (expression mean±SD): I group 17.1 ±12.9%, II group 46.4 ±17.9%, III group 3 ±2.6%; CD24: I group 2.9 ±3.3%, II group 14.9 ±18.1%, III group 0%). In ovarian cancer the CD44-/CD24+ phenotype was more characteristic for low differentiated cases (CD44: I group 0%, II group 2.3 ±4.9%, III group 28.7 ±10.8%; CD24: I group 48.5 ± 18.6%, II group 1.8 ±2.3%, III group 0%). Discussions Assuming that low differentiated cancer should contain more cancer stem cells, CD44±/CD24-/low cells cannot be regarded to as cancer stem cells in ovarian and uterine cancer. High expression of CD44 in high differentiated and borderline ovarian cancers and low expression of CD24 in low differentiated cases should further be studied. CD44 and CD24 are two markers that are currently supposed to be expressed in certain combinations (CD44+/CD24-/low) in cells with stem-cell properties in different types of cancer. Our research was focused on identification of these two markers in ovarian and uterine cancer. The archived materials of formalin-fixed, paraffin-embedded tissues were used for research. The cases were divided according to the morphologic differentiation: low (I group), moderate (II group) and high differentiated (III group) variants (10 cases of each type). The H&E and CD24/CD44 immunohistochemically stained parallel slices were evaluated. The results showed non-specific expression features in uterine cancer cases [CD44 (expression mean±SD): I group 17.1 ±12.9%, II group 46.4 ±17.9%, III group 3 ±2.6%; CD24: I group 2.9 ±3.3%, II group 14.9 ±18.1%, III group 0%). In ovarian cancer the CD44-/CD24+ phenotype was more characteristic for low differentiated cases (CD44: I group 0%, II group 2.3 ±4.9%, III group 28.7 ±10.8%; CD24: I group 48.5 ± 18.6%, II group 1.8 ±2.3%, III group 0%). Assuming that low differentiated cancer should contain more cancer stem cells, CD44±/CD24-/low cells cannot be regarded to as cancer stem cells in ovarian and uterine cancer. High expression of CD44 in high differentiated and borderline ovarian cancers and low expression of CD24 in low differentiated cases should further be studied.
Publication Year: 2014
Publication Date: 2014-01-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot